Related Experiment Video
Updated: May 23, 2026
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
CD44 antibody-targeted liposomal nanoparticles for molecular imaging and therapy of hepatocellular carcinoma
1Department of Immunology, Nankai University School of Medicine, Tianjin 300071, China.
Abstract:
Most hepatocellular carcinoma (HCC) therapies fail to target cancer stem cells (CSCs) and monitor cancer progression or regression. The purpose of this study was to evaluate the possibility of cancer imaging and simultaneously monitoring targeted therapy in a single animal by anti-CD44 antibody-mediated liposomal nanoparticle. In this study, an in situ liver tumor model was applied for therapy by injecting 1.0 × 10(6) HepG2 cells carrying a reporter system encoding a double fusion (DF) reporter gene consisting of firefly luciferase (Fluc) and green fluorescent protein (GFP) into the liver of NOD/SCID mice. A strategy was developed which specifically targeted HCC via anti-CD44 antibody-mediated liposomal nanoparticle delivery, loaded of either doxorubicin (Dox) or a triple fusion (TF) gene containing the herpes simplex virus truncated thymidine kinase (HSV-ttk) and renilla luciferase (Rluc) and red fluorescent protein (RFP). The NOD/SCID mice were subsequently treated with ganciclovir (GCV) and the growth status of tumor was monitored by optical bioluminescence imaging (BLI) of Fluc and specific targeting of the liposomal nanoparticle was tracked by Rluc imaging. CD44 antibody-mediated liposomal nanoparticle, loaded of TF plasmids, were shown to be useful for monitoring and evaluating targeting efficacy and gene therapy by non-invasive molecular imaging. Here, we demonstrate the time intensive preclinical steps involved in molecular target identification, validation, and characterization by dual molecular imaging. This targeted and traceable therapeutic strategy has potential advantages to overcome the problems of conventional tumor therapy and may open a new application for the treatment of HCC by targeting CSCs.
Insights
This study developed a targeted nanoparticle therapy for hepatocellular carcinoma (HCC) that simultaneously images cancer progression and monitors treatment effectiveness. This novel approach targets cancer stem cells (CSCs) for improved therapeutic outcomes.
Area of Science:
- Oncology
- Nanomedicine
- Molecular Imaging
Background:
- Hepatocellular carcinoma (HCC) treatments often fail to target cancer stem cells (CSCs) and monitor treatment response.
- Developing effective therapies requires strategies that can simultaneously image cancer and track therapeutic efficacy.
Purpose of the Study:
- To evaluate anti-CD44 antibody-mediated liposomal nanoparticles for targeted HCC therapy and simultaneous cancer imaging.
- To assess the feasibility of non-invasive monitoring of targeted gene therapy and nanoparticle delivery in vivo.
Main Methods:
- An in situ liver tumor model was established in NOD/SCID mice using HepG2 cells with a dual-fusion (DF) reporter gene (firefly luciferase/green fluorescent protein).
- Liposomal nanoparticles were engineered to target HCC via anti-CD44 antibodies, loaded with doxorubicin (Dox) or a triple-fusion (TF) gene (herpes simplex virus thymidine kinase/renilla luciferase/red fluorescent protein).
- Tumor growth was monitored using bioluminescence imaging (BLI) of Fluc, and nanoparticle targeting was tracked via Rluc imaging after ganciclovir (GCV) treatment.
Main Results:
- Anti-CD44 antibody-mediated liposomal nanoparticles loaded with TF plasmids demonstrated utility in monitoring and evaluating gene therapy targeting efficacy.
- Dual molecular imaging allowed for non-invasive tracking of both tumor status and nanoparticle biodistribution.
- The study successfully characterized preclinical molecular targets and validated the dual imaging approach.
Conclusions:
- Targeted, traceable nanomedicine offers a promising strategy to overcome limitations of conventional HCC therapies.
- This approach, by targeting CSCs and enabling simultaneous imaging and therapy monitoring, presents a new avenue for HCC treatment.
- The developed dual molecular imaging technique facilitates efficient preclinical evaluation of targeted nanotherapeutics.
More Related Videos
08:55Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
Published on: April 15, 2016
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
